QUVIVIQ™ is indicated for the treatment of adult patients with insomnia, characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ,. | June 12, 2023
Idorsia Pharmaceuticals Ltd: Idorsia launches QUVIVIQ (daridorexant) in Switzerland - a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Bimekizumab is the first and only IL-17A and IL-17F inhibitor approved in the European Union for active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA)Approval in PsA is supported by two Phase 3 studies where bimekizumab showed improvements vs. placebo in joint and skin symptoms across biologic.
adults with severe active AS who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs . Axial spondyloarthritis without. | May 30, 2023
New research has led to the development of an algorithm designed to help improve detection of allergic reactions to antibiotics, given that antibiotics are among the most common medication adverse event causes.